Publication date: Dec 10, 2025
This cross-sectional study was conducted among hospital staff during the COVID-19 pandemic to assess the prevalence of dry eye disease (DED) symptoms, associated risk factors, and their impact on quality-of-life (QOL). Data were collected via an internet-based survey at a tertiary care hospital from February to June 2022. Participants completed the Thai version of the Dry Eye-related Quality of Life Score (DEQS-Th) to identify DED symptoms, and measures of general QOL and mental health were evaluated using the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) and Thymometer questionnaires. Of the 1,250 participants (mean age of 39. 9 years; 79% female), the prevalence of DED symptoms was 62. 1% (95% CI 59. 4-64. 7%). The mean DEQS-Th score was significantly higher among those with DED (37. 7 +/- 14. 6) compared to those without (8. 0 +/- 5. 3). Multivariable analysis identified several factors significantly associated with DED symptoms, including female gender (p = 0. 005), systemic atopy (p = 0. 02), preexisting dry eye (p
Open Access PDF
| Concepts | Keywords |
|---|---|
| February | COVID-19 |
| Hospital | Dry eye disease |
| June | Hospital personnel |
| Thai | Quality of life |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | dry eye disease |
| drug | DRUGBANK | Etoperidone |
| disease | MESH | COVID-19 pandemic |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| drug | DRUGBANK | Coenzyme M |